×
About 33,567 results

ALLMedicine™ Hodgkin Lymphoma Center

Research & Reviews  15,523 results

Successful treatment of EBV-associated Primary CNS Lymphoma due to PTLD, with Ibrutinib...
https://doi.org/10.1111/ajt.16628
American Journal of Transplantation : Official Journal Of... Law SC, Hoang T et. al.

May 4th, 2021 - Primary central nervous system lymphoma (PCNSL) occurring following organ transplantation (post-transplantation lymphoproliferative disorder 'PTLD') is a highly aggressive non-Hodgkin lymphoma. It is typically treated with high-dose methotrexate-b...

Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: a comprehensive review.
https://doi.org/10.1111/cas.14933
Cancer Science; Yasuda H, Yasuda M et. al.

May 3rd, 2021 - Chemotherapy for non-Hodgkin lymphoma (NHL) in the hemodialysis (HD) patient is a challenging situation. Because many drugs are predominantly eliminated by the kidneys, chemotherapy in the HD patient requires special considerations concerning dose...

Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refrac...
https://doi.org/10.1111/cas.14915
Cancer Science; Liu M, Deng H et. al.

May 1st, 2021 - The efficacy and side effects of the second-time humanized CD19 chimeric antigen receptor (CD19-CAR) T-cell therapy after unsuccessful first-time anti-CD19-CAR T-cell therapy and subsequent ibrutinib salvage treatment were observed in patients wit...

FDG PET/CT to detect bone marrow involvement in the initial staging of patients with ag...
https://doi.org/10.1007/s00259-021-05348-6 10.1111/j.1600-0609.1997.tb00982.x 10.1182/blood-2011-02-335794 10.2967/jnumed.112.114710
European Journal of Nuclear Medicine and Molecular Imaging; Kaddu-Mulindwa D, Altmann B et. al.

Apr 30th, 2021 - Fluorine-18 fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG PET/CT) is the standard for staging aggressive non-Hodgkin lymphoma (NHL). Limited data from prospective studies is available to determine whether i...

The evolving role of allogeneic haematopoietic cell transplantation in the era of chima...
https://doi.org/10.1111/bjh.17460
British Journal of Haematology; Dholaria B, Savani BN et. al.

Apr 30th, 2021 - Chimaeric antigen receptor T-cell (CAR T) therapy has revolutionized the management of many haematological malignancies. It is associated with impressive disease responses in relapsed or refractory high-grade B-cell non-Hodgkin lymphoma (B-NHL) an...

see more →

Guidelines  111 results

Adult Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq?cid=eb_govdel
National Cancer Institute

Jan 14th, 2021 - More than 75% of all newly diagnosed patients with adult HL can be cured with combination chemotherapy and/or radiation therapy.[2] Over the last five decades, U.S. national mortality has fallen more rapidly for adult HL than for any other maligna...

Lisocabtagene maraleucel CAR T shows durable response in large B-cell NHL
https://www.healio.com/news/hematology-oncology/20200709/lisocabtagene-maraleucel-car-t-shows-durable-response-in-large-bcell-nhl

Jul 8th, 2020 - In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.

Pembrolizumab prolonged PFS vs. brentuximab vedotin in r/r Hodgkin lymphoma
https://www.mdedge.com/hematology-oncology/article/223065/hodgkin-lymphoma/pembrolizumab-prolonged-pfs-vs-brentuximab

May 31st, 2020 - Pembrolizumab treatment significantly improved progression-free survival versus brentuximab vedotin in a recent randomized, phase 3 trial including patients with relapsed or refractory classical Hodgkin lymphoma, an investigator has reported.

CAR-T continues to show durable responses in indolent non-Hodgkin lymphoma
https://www.healio.com/hematology-oncology/lymphoma/news/online/{b5b2d115-7000-4df9-8743-26711c3bbde1}/car-t-continues-to-show-durable-responses-in-indolent-non-hodgkin-lymphoma

May 30th, 2020 - Axicabtagene ciloleucel induced a 93% response rate among patients with relapsed or refractory indolent non-Hodgkin lymphoma, according to interim results of the phase 2 ZUMA-5 trial presented during the ASCO20 Virtual Scientific Program.

CAR T-Cell Therapy Impresses in Indolent NHL
https://www.medpagetoday.com/meetingcoverage/asco/86783

May 30th, 2020 - Almost 100% of patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) responded to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta), data from an ongoing study showed.

see more →

Drugs  93 results see all →

Clinicaltrials.gov  16,739 results

Successful treatment of EBV-associated Primary CNS Lymphoma due to PTLD, with Ibrutinib...
https://doi.org/10.1111/ajt.16628
American Journal of Transplantation : Official Journal Of... Law SC, Hoang T et. al.

May 4th, 2021 - Primary central nervous system lymphoma (PCNSL) occurring following organ transplantation (post-transplantation lymphoproliferative disorder 'PTLD') is a highly aggressive non-Hodgkin lymphoma. It is typically treated with high-dose methotrexate-b...

Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: a comprehensive review.
https://doi.org/10.1111/cas.14933
Cancer Science; Yasuda H, Yasuda M et. al.

May 3rd, 2021 - Chemotherapy for non-Hodgkin lymphoma (NHL) in the hemodialysis (HD) patient is a challenging situation. Because many drugs are predominantly eliminated by the kidneys, chemotherapy in the HD patient requires special considerations concerning dose...

Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refrac...
https://doi.org/10.1111/cas.14915
Cancer Science; Liu M, Deng H et. al.

May 1st, 2021 - The efficacy and side effects of the second-time humanized CD19 chimeric antigen receptor (CD19-CAR) T-cell therapy after unsuccessful first-time anti-CD19-CAR T-cell therapy and subsequent ibrutinib salvage treatment were observed in patients wit...

FDG PET/CT to detect bone marrow involvement in the initial staging of patients with ag...
https://doi.org/10.1007/s00259-021-05348-6 10.1111/j.1600-0609.1997.tb00982.x 10.1182/blood-2011-02-335794 10.2967/jnumed.112.114710
European Journal of Nuclear Medicine and Molecular Imaging; Kaddu-Mulindwa D, Altmann B et. al.

Apr 30th, 2021 - Fluorine-18 fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG PET/CT) is the standard for staging aggressive non-Hodgkin lymphoma (NHL). Limited data from prospective studies is available to determine whether i...

The evolving role of allogeneic haematopoietic cell transplantation in the era of chima...
https://doi.org/10.1111/bjh.17460
British Journal of Haematology; Dholaria B, Savani BN et. al.

Apr 30th, 2021 - Chimaeric antigen receptor T-cell (CAR T) therapy has revolutionized the management of many haematological malignancies. It is associated with impressive disease responses in relapsed or refractory high-grade B-cell non-Hodgkin lymphoma (B-NHL) an...

see more →

News  1,097 results

FDA Approves Loncastuximab for Diffuse Large B-Cell Lymphomas
https://www.medscape.com/viewarticle/949934

Apr 25th, 2021 - The US Food and Drug Administration granted an accelerated approval April 24 for a new drug for use in patients with relapsed/refractory diffuse large B-cell lymphomas (DLBCL) who have tried at least two prior systemic therapies. The new product, ...

Combo Provides 'Broad Benefit' Across NHL Subtypes
https://www.medscape.com/viewarticle/949208

Apr 12th, 2021 - The combination of copanlisib plus rituximab led to a 48% reduction in the risk of disease progression or death, when compared with rituximab plus placebo in a phase 3 trial of patients with relapsed, indolent non-Hodgkin lymphoma (NHL). The trial...

Remission of Hodgkin Lymphoma After COVID-19
https://www.medscape.com/viewarticle/945856

Feb 15th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Patients with cancer are considered at risk for COVID-19, but in some cases, could the infection be a good thing? A case report of a patient with ...

Anti-CD20 Therapy for Lymphoma Tied to Worse COVID-19 Outcomes
https://www.medscape.com/viewarticle/945496

Feb 8th, 2021 - NEW YORK (Reuters Health) - Lymphoma patients treated with B-cell-depleting anti-CD20 monoclonal antibodies, such as rituximab or obinutuzumab, may have worse outcomes from COVID-19 infection, according to a study from France. "More than 20 years ...

Fast Five Quiz: Waldenström Macroglobulinemia Workup
https://reference.medscape.com/viewarticle/944100

Jan 31st, 2021 - Waldenström macroglobulinemia (WM) is an indolent subtype of non-Hodgkin lymphoma (NHL) that affects small lymphocytes. WM is rare, accounting for approximately 2% of hematologic malignancies with 1500 cases diagnosed per year in the United States...

see more →

Patient Education  4 results see all →